Broken String Biosciences

Broken String Biosciences develops biopharmaceutical products and cell therapies using genome sequencing data, having developed INDUCE-seq technology for measuring DNA breaks throughout the genome. This technology determines the mechanism of double-strand break repair, facilitating the development of therapeutic genome editing for cancer, immunological health, and other diseases. Founded in 2020 and headquartered in Cambridge, United Kingdom, Broken String Biosciences has raised approximately $15M in Series A funding from investors including Illumina, Illumina Ventures, Merieux Equity Partners, Tencent, Dieter von Holtzbrinck Ventures, and HERAN Partners. The company's sequencing technology enables precise characterization of off-target effects in gene editing, addressing a critical safety requirement for the development of CRISPR-based therapeutics by providing comprehensive genome-wide assessment of DNA damage patterns caused by gene editing tools.